Revenue
2020
2021
2022
2023
2024
2025
Arcutis Biotherapeutics, Inc. (ARQT)
Price$23.90Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $372.1M | $166.5M | $29.2M | $3.7M | $0 | $0 | — | — |
| Gross profit | $335.4M | $147.4M | $24.2M | $2.9M | $0 | — | — | — |
| Gross margin | 90.14% | 88.51% | 82.91% | 79.54% | — | — | — | — |
| Research & development | $77.1M | $76.4M | $110.6M | $182.4M | $145.6M | $115.3M | $36.5M | $17.9M |
| Operating expenses | $347.6M | $275.8M | $265.3M | $305.3M | $206.5M | $136.6M | $43.1M | $19.7M |
| Operating income | −$12.2M | −$128.4M | −$241.1M | −$301.6M | −$206.5M | −$136.6M | −$43.1M | −$19.7M |
| Operating margin | −3.29% | −77.10% | −826.08% | −8,183.04% | — | — | — | — |
| EBITDA | −$6.9M | −$125.8M | −$239.6M | −$300.7M | −$206.1M | −$136.5M | −$43.1M | −$19.7M |
| EBITDA margin | −1.84% | −75.56% | −820.77% | −8,157.70% | — | — | — | — |
| Net income | −$16.1M | −$140.0M | −$262.1M | −$311.5M | −$206.4M | −$135.7M | −$42.0M | −$19.3M |
| Net profit margin | −4.34% | −84.09% | −898.17% | −8,449.76% | — | — | — | — |
| Basic EPSper basic share | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | -$15.53 |
| Diluted EPSper diluted share | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | -$15.53 |
Owners
Reported shareholders
9.90%of listed shares
MONTANOVA CAPITAL, LLC12.44M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MONTANOVA CAPITAL, LLC | 9.90%12.44M shares |
BlackRock, Inc. | 8.40%10.55M shares |
Frazier Life Sciences Management, L.P. | 7.86%9.87M shares |
Rubric Capital Management LP | 6.59%8.27M shares |
Polar Capital Holdings Plc | 5.26%6.61M shares |
STATE STREET CORP | 4.64%5.82M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.97%4.99M shares |
MORGAN STANLEY | 3.54%4.45M shares |
JENNISON ASSOCIATES LLC | 3.36%4.22M shares |
D. E. Shaw & Co., Inc. | 3.14%3.95M shares |
UBS Group AG | 2.65%3.33M shares |
BANK OF AMERICA CORP /DE/ | 2.38%2.99M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.37%2.98M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.93%2.43M shares |
ORBIMED ADVISORS LLC | 1.63%2.04M shares |
FRANKLIN RESOURCES INC | 1.54%1.93M shares |
AMERICAN CENTURY COMPANIES INC | 1.53%1.93M shares |
GOLDMAN SACHS GROUP INC | 1.33%1.67M shares |
Jupiter Topco LLC | 1.12%1.41M shares |
OBERWEIS ASSET MANAGEMENT INC/ | 1.09%1.37M shares |
Percentages use 125.59M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Welgus Howard G.Director | SellCommon Stock | 635 | $25.67 | $16.3K | 37.7K |
| Jun 15, 2026Form 4 · 10b5-1 | LIN SUE-JEANDirector | SellCommon Stock | 4.9K | $24.38 | $120.6K | 27.6K |
| Jun 15, 2026Form 4 · 10b5-1 | Welgus Howard G.Director | SellCommon Stock | 4.1K | $24.41 | $100.0K | 38.4K |
| May 11, 2026Form 4 · 10b5-1 | Vairavan LathaSVP Chief Financial Officer | SellCommon Stock | 435 | $21.05 | $9.2K | 86.0K |
| May 11, 2026Form 4 · 10b5-1 | Burnett PatrickSee Remarks | SellCommon Stock | 222 | $21.05 | $4.7K | 120.2K |